Table of Contents Author Guidelines Submit a Manuscript
Journal of Osteoporosis
Volume 2010, Article ID 747852, 7 pages
Research Article

Superparamagnetic Bifunctional Bisphosphonates Nanoparticles: A Potential MRI Contrast Agent for Osteoporosis Therapy and Diagnostic

1Laboratoire CSPBAT, C2B, FRE 3043 CNRS, Université Paris 13, 93017 Bobigny Cedex, France
2Service de Médecine Nucléaire, Hôpital Avicenne, APHP, 93009 Bobigny Cedex, France
3Service de Radiologie, Hôpital Bichat, APHP, U 698 ISERM, Université Paris 7, 75877 Paris Cedex 18, France
4UPRES 3410 Biothérapies Bénéfices et Risques, Université Paris 13, 93017 Bobigny Cedex, France
5Plateforme d'IRM du Petit Animal, U 970 INSERM, Université Paris 5, 75908 Paris Cedex 10, France

Received 14 January 2010; Revised 3 March 2010; Accepted 19 April 2010

Academic Editor: Annie Kung

Copyright © 2010 Y. Lalatonne et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


A bone targeting nanosystem is reported here which combined magnetic contrast agent for Magnetic Resonance Imaging (MRI) and a therapeutic agent (bisphosphonates) into one drug delivery system. This new targeting nanoplatform consists of superparamagnetic nanoparticles conjugated to 1,5-dihydroxy-1,5,5-tris-phosphono-pentyl-phosphonic acid (di-HMBPs) molecules with a bisphosphonate function at the outer of the nanoparticle surface for bone targeting. The as-synthesized nanoparticles were evaluated as a specific MRI contrast agent by adsorption study onto hydroxyapatite and MRI measurment. The strong adsorption of the bisphosphonates nanoparticles to hydroxyapatite and their use as MRI contrast agent were demonstrated. Cellular tests performed on human osteosarcoma cells (MG63) show that @di-HMBP hybrid nanomaterial has no citoxity effect in cell viability and may act as a diagnostic and therapeutic system.